Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bionor Pharma is set to initiate a double blinded, randomized and placebo-controlled trial to evaluate HIV-vaccine candidate Vacc-4x in combination with Revlimid.
Subscribe to our email newsletter
Revlimid is indicated as a treatment for multiple myeloma and anemia due to myelodysplastic syndrome linked with a deletion in the long arm of the fifth chromosome.
In the trial, around 12 patients will be given Vacc-4x in conjunction with Revlimid, however other set of 12 patients will receive Vacc-4x alone.
The study aims to establish the ability of Vacc-4x in improving immune function in patients that fail to regain a healthy immune defense despite that their viral load is well controlled on conventional HIV-medicines (antiretroviral therapy – ART).
The study will also evaluate the effect of Revlimid on Vacc-4x’s ability to improve immune function.
Bionor CSO Maja Sommerfelt said the use of a therapeutic vaccine combined with modulation of the immune system resonates well with the current thinking in the scientific community.